Navinta

Navinta is a US-based, private generic drug company specializing in complex generics, novel formulations, and API manufacturing. With a foundation in 2003, it has built a portfolio of 16 approved ANDA products, 43 patents, and 36 active Drug Master Files. The company's strategy focuses on difficult-to-make products in areas like analgesics, cardiovascular agents, and cytotoxic anticancer drugs, utilizing both ANDA and NDA pathways. Its operations encompass internal R&D, a DEA-registered facility for controlled substances, and a global network of qualified contract manufacturers.

Platform for developing complex generic formulations, novel drug delivery systems (e.g., sprays), and specialized API manufacturing (cytotoxic, sterile, controlled substances).

Navinta competes with large, diversified generic manufacturers (e.g., Teva, Mylan) and other complex generics specialists (e.g., Hikma, Lannett). Its niche in cytotoxic and controlled substance APIs provides some differentiation. Competition is based on regulatory speed, manufacturing cost, technological capability, and the ability to successfully litigate or circumvent patents.